Search the Newsreel

Mirum Pharmaceuticals (MIRM) Stock Looks Fairly Valued After Recent News

Mirum Pharmaceuticals (MIRM) stock is currently considered fairly valued despite significant share price gains over the past five years. The company's P/S ratio of 10.4x is below the biotech industry average, suggesting it might still be on the inexpensive side. The future performance of …

Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next

Mirum Pharmaceuticals (MIRM) saw its stock drop 6.4% despite raising its 2026 net product sales guidance, due to reporting significantly wider net losses in the second quarter of 2026. The company highlighted progress with breakthrough therapy designation for volixibat and potential launch timing for …

Janus Henderson Group (MIRM) reports 5.9M Mirum Pharma shares under management

Janus Henderson Group Ltd., through its asset management subsidiaries, reported beneficial ownership of 5,909,184 shares of Mirum Pharmaceuticals, Inc. common stock, representing 9.7% of the class as of June 30, 2026. These shares are managed in client accounts (Managed Portfolios) where Janus Henderson holds …

Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals, a rare disease company, announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. The presentation will be webcast live on Mirum's corporate website. The company is known for its approved products for …

Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 6,001 Shares of Stock

Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt sold 6,001 shares of the company's stock for approximately $599,500, reducing his direct ownership by 14.17%. This transaction was conducted under a pre-arranged Rule 10b5-1 plan. Despite the insider sale and an earnings miss, analysts maintain a "Moderate …

Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript

Mirum Pharmaceuticals (MIRM) reported strong Q2 2026 results with $176.2 million in net product sales, leading to an increased full-year guidance of $680 million to $700 million. The company is advancing its pipeline, including Zilurgisertib for FOP with a September PDUFA date, and addressing …

Mirum Pharmaceuticals (MIRM) CFO sells 6,001 shares in Rule 10b5-1 trade

Mirum Pharmaceuticals' CFO, Eric Bjerkholt, sold 6,001 shares of common stock on August 11, 2026, at a weighted average price of $99.90 per share. This transaction was conducted under a Rule 10b5-1 trading plan established on March 9, 2026. Following the sale, Bjerkholt beneficially …

Mirum Pharmaceuticals CEO Christopher Peetz sells $1.98 million in shares

Mirum Pharmaceuticals CEO Christopher Peetz sold 20,000 shares of the company's common stock for approximately $1.98 million under a pre-arranged trading plan. Concurrently, he acquired 20,000 shares through the exercise of employee stock options for $58,720. Despite a recent stock pullback and an "overvalued" …

Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 20,000 Shares of Stock

Mirum Pharmaceuticals CEO Christopher Peetz sold 20,000 shares of the company's stock for approximately $1.98 million on August 10th, 2026, under a pre-arranged Rule 10b5-1 trading plan. This transaction reduced his direct ownership by 9.33% to 194,309 shares. Despite Mirum missing analysts' EPS estimates …

Mirum Pharmaceuticals (MIRM) CEO trades 20,000 shares after option exercise under 10b5-1 plan

Mirum Pharmaceuticals, Inc. CEO Christopher Peetz exercised an employee stock option for 20,000 shares at $2.936 per share and subsequently sold all 20,000 shares in three tranches at weighted average prices between $98.51 and $100.14. These transactions, which occurred on August 10, 2026, were …

MIRM (MIRM) insider files to sell 6,001 shares after recent stock sales

An insider at Mirum Pharmaceuticals (MIRM), Eric Bjerkh olt, has filed a notice to sell 6,001 shares of common stock with an aggregate market value of $599,509.50. This proposed sale follows two previous sales by the same insider within the last three months, totaling …

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., August 11, 2026--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on August 10, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 26,050 shares of …

What is HC Wainwright's Forecast for MIRM FY2026 Earnings?

Mirum Pharmaceuticals Stock Sinks as Widening Quarterly Loss Offsets Raised Full-Year Sales Guidance

Hennion & Walsh Asset Management Inc. Sells 56,100 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Hennion & Walsh Asset Management Inc. reduced its stake in Mirum Pharmaceuticals (NASDAQ:MIRM) by 59.9%, selling 56,100 shares and retaining 37,492 shares valued at $4.39 million. This divestment occurred despite Mirum's Q2 revenue beating estimates and management raising its 2026 sales outlook. However, the …

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Encompass Health (EHC)

Two healthcare companies, Mirum Pharmaceuticals (MIRM) and Encompass Health (EHC), have received bullish analyst ratings. TD Cowen maintained a Buy rating for Mirum with a $140.00 price target, and a Strong Buy consensus suggests a 44.8% upside. Encompass Health also received a Buy rating …

MIRM (MIRM) insider Christopher Peetz plans 20,000-share sale after option exercise

Christopher Peetz, an insider at Mirum Pharmaceuticals (MIRM), has filed a Form 144 indicating his intent to sell 20,000 shares of common stock through Morgan Stanley Smith Barney LLC on or after August 10, 2026, following a stock option exercise. The filing also reports …

Mirum Pharmaceuticals (MIRM) Is Down 5.0% After Wider Losses and Volixibat Delay - What's Changed

Mirum Pharmaceuticals reported wider net losses in Q2 2026, reaching US$857.38 million for the first half of the year, despite raising full-year product sales guidance to US$680-US$700 million. The company's stock fell 5.0% due to these losses and a significant delay in the FDA's …

Wall Street Zen Upgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to "Hold"

Wall Street Zen has upgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "sell" to "hold" despite broader analyst coverage maintaining a "Moderate Buy" rating with a $137.33 price target. This upgrade comes as Mirum Pharmaceuticals reported better-than-expected second-quarter revenues of $176.24 million, a 37.9% year-over-year increase, though …

The Manufacturers Life Insurance Company Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM

The Manufacturers Life Insurance Company significantly increased its stake in Mirum Pharmaceuticals (NASDAQ: MIRM) by 63.3% in the first quarter, now holding 55,693 shares valued at $5.15 million. Despite Mirum's Q2 revenue beating estimates at $176.2 million and raised 2026 revenue guidance, the company …

MIRUM PHARMACEUTICALS, INC. : RAYMOND JAMES RAISES TARGET PRICE TO $183 FROM $165

Raymond James has increased its target price for MIRUM Pharmaceuticals, Inc. (MIRUM) from $165 to $183. This update indicates a positive outlook from the financial firm regarding the pharmaceutical company's future performance. The article itself is very brief, consisting only of this announcement.

Mirum Pharmaceuticals (MIRM) Stock Sinks As Losses Deepen Despite Higher Guidance

Insmed Catapults 34%, Leading A Biotech Rally. But Mirum Takes A Bath.

Insmed stock led a biotech rally Thursday, catapulting 34% on solid second-quarter sales for its new lung disease drug, Brinsupri. Continue Reading

MIRUM PHARMACEUTICALS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $140 FROM $185

H.C. Wainwright has reduced its target price for Mirum Pharmaceuticals Inc. (MIRM.O) from $185 to $140. This announcement was made on August 6, 2026, according to a Reuters report published on Bitget News. The article explicitly states that its content reflects the author's opinion …

Mirum Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $138.21, Implies 31% Upside

Mirum Pharmaceuticals, Inc.'s average 12-month price target has been lowered to $138.21 from $145.29, according to 14 analysts. Despite the cut, the new target still suggests a 31% potential upside from the Aug. 5 closing price. The consensus rating remains a "Buy" across all …

Mirum Pharmaceuticals Slides as FDA Feedback Clouds Volixibat Timeline

Mirum Pharmaceuticals (MIRM) stock dropped 10.4% after the FDA recommended a Phase 3 study for its drug volixibat, delaying its potential NDA submission despite strong second-quarter sales and raised full-year guidance. The regulatory setback for volixibat, intended for cholestatic pruritus due to PSC, has …

RBC Capital Adjusts Mirum Pharmaceuticals PT to $135 From $148, Maintains Outperform Rating

RBC Capital has lowered its price target for Mirum Pharmaceuticals (MIRM) from $148 to $135, while still maintaining an Outperform rating on the stock. This adjustment comes after the company recently reported its Q2 2026 earnings, which showed a wider loss despite increased revenue. …

FMR LLC reveals 6.2% Mirum Pharmaceuticals (MIRM) ownership in Schedule 13G

FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 3,777,851.04 shares of Mirum Pharmaceuticals Inc. (MIRM) common stock, which represents 6.2% of the class. Abigail P. Johnson also holds sole dispositive power over the same number of shares. The filing indicates …

Mirum Pharmaceuticals Q2 2026 Earnings Call Transcript

Mirum Pharmaceuticals reported strong Q2 2026 results, with net product sales of $176 million, and raised its full-year guidance to $680 million-$700 million. The company is preparing for the potential Q4 U.S. launch of zilurgisertib for FOP, following a favorable FDA meeting. However, the …

Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15%

Shares of Mirum Pharmaceuticals (MIRM) dropped 15% after the FDA requested an additional Phase 3 trial for its lead candidate, Volixibat, delaying its potential new drug application until the first half of 2027. Despite this setback, the company raised its full-year 2026 net product …

Mirum Pharmaceuticals earnings missed by $0.32, revenue topped estimates

Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Earnings Results, Misses Estimates By $0.32 EPS

Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics

Mirum Pharmaceuticals, Inc. (MIRM) reported $176.24 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 37.9%. EPS of -$0.80 for the same period compares to -$0.12 a year ago. The reported revenue represents a surprise of +6.97% over the …